Name

Pfizer Indonesia

Legal name

PT Pfizer Indonesia

Website

https://pfizer.co.id

Company type

Private

Founded year

1969

Operating status

Operating

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

akta.pro secondary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Prescription pharmaceuticals
• Vaccine manufacturing
• Biopharmaceutical products
• Oncology treatments
• National immunization programs

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical and Vaccine Product Sales: Pfizer Indonesia generates revenue through the sale of prescription medicines and vaccines. Products include antibiotics, oncology drugs, cardiovascular treatments, hemophilia treatments, and pneumococcal vaccines (PCV). Products are distributed to hospitals, clinics, government immunization programs, and through retail pharmacy channels. The company supplies over 1.6 million PCV vaccine vials for Indonesia's national immunization program.
2. Licensing and Distribution: Pfizer Indonesia operates as the licensed distributor and manufacturer for Pfizer's global pharmaceutical portfolio in Indonesia, leveraging the parent company's proprietary drug development pipeline and regulatory approvals.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels11 records

Core offering

Pfizer Indonesia manufactures and distributes prescription medicines and vaccines for the Indonesian market, including antibiotics, oncology drugs, cardiovascular treatments, hemophilia treatments, and pneumococcal conjugate vaccines (PCV). The company operates a GMP-certified manufacturing facility (Pfizer Global Supply Jakarta) since 1971, producing pharmaceuticals for domestic distribution and export to Philippines, Hong Kong, Malaysia, Singapore, Thailand, and South Korea.

Product overview

Pfizer Indonesia operates as a pharmaceutical company within the Pfizer global network, focusing on manufacturing and distributing prescription medications and vaccines. The company's core offerings include pharmaceutical products for various therapeutic areas (infectious diseases, cancer, cardiovascular diseases, hemophilia), vaccines including Pneumococcal Conjugate Vaccine (PCV), and patient assistance programs. Pfizer Indonesia also provides digital platforms including PfizerPro for healthcare professionals and Sahabat Peduli for public health education. The company operates a manufacturing facility in Jakarta (Pfizer Global Supply) producing medicines for local distribution and export to Philippines, Hong Kong, Malaysia, Singapore, Thailand, and South Korea.

Differentiator

Problem solved

Functional benefit

Brands

• PfizerPro: Digital platform for healthcare professionals providing information about innovative therapies, clinical trial data, real-world data, and patient assistance programs.
• Sahabat Peduli #SelaluHadirDisampingmu
• Pfizer Biotech Fellowship
• HigherHeight
• Pfizer Indonesia Women Forum (PIWF)

Products and services

• Pneumococcal Conjugate Vaccine (PCV) Pneumococcal conjugate vaccine supplied to Indonesia's national immunization program, with over 1.6 million multidose vials in shipment process during 2022.
• Oncology Pharmaceuticals Cancer treatment medicines distributed to hospitals and healthcare providers in Indonesia, supporting late-stage cancer care including metastatic breast cancer and lung cancer.
• Cardiovascular Treatments Cardiovascular disease medicines supplied through hospital networks, pharmacies, and healthcare providers in Indonesia.
• Hemophilia Treatments Hemophilia medicines distributed to hospitals and treatment centers serving hemophilia patients in Indonesia.
• Antibiotic Pharmaceuticals Antibiotic medicines for infectious disease treatment distributed to hospitals, clinics, and pharmacies in Indonesia.

Quantifiable outcome

• Trained over 14,000 people including employees, healthcare workers, researchers, lecturers, and students in 2021 alone
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered minor, major and core.

• Rise Against HungerminorOthers · 1 December 2022Pfizer Indonesia partnered with Rise Against Hunger to package 75,000 nutritious food packets during the 175 Days of Good CSR initiative. Over 200 Pfizer Indonesia employees participated in the meal packaging activity held in Yogyakarta on December 15, 2022, with food packets distributed to underprivileged families.
• PT Prodia Widyahusada TbkmajorStrategic or Co-development Partner · 11 November 2022Pfizer and Prodia signed a 1-year MOU to increase public awareness of pneumonia and its prevention. The partnership develops online and offline pneumonia awareness programs for healthcare professionals and the general public, includes B2B partnerships for corporate clients, and offers pneumococcal vaccination packages for Prodia customers across its 260+ outlets nationwide.
• Ikatan Program Studi Bioteknologi Indonesia (IPSBI)coreStrategic or Co-development Partner · 1 October 2022Pfizer Indonesia partnered with IPSBI to organize the HigherHeight 2022 program, focusing on capacity building for biotechnology lecturers and researchers across 15+ Indonesian universities. IPSBI is an association of biotechnology study programs from universities across Indonesia, initiated to standardize curriculum and promote biotechnology education excellence.
• US-ASEAN Business Council (USABC)minorGTM or Marketing Partner · 1 August 2022Pfizer Indonesia participated in the annual USABC mission to Indonesia, meeting with President Joko Widodo to discuss Pfizer's commitment to supporting Indonesian healthcare human capacity development. The company trained over 14,000 people in Indonesia in 2021 through various programs.
• PT Lippo General Insurance TbkmajorGTM or Marketing Partner · 22 June 2022Pfizer and Lippo General Insurance signed a 2-year MOU to improve financial and health literacy among Indonesians. Collaboration includes joint webinars, forums, communication programs, and socialization activities to raise awareness about health prevention and treatment options. The partnership aims to develop programs, guidelines, products, and services addressing Indonesian healthcare needs.
• Direct ReliefmajorStrategic or Co-development Partner · 1 February 2022Pfizer partnered with Direct Relief, a humanitarian nonprofit organization, to donate COVID-19 medications to Indonesia. Donated medicines were shipped to Muhammadiyah Disaster Management Center (MDMC) warehouses in Jakarta and distributed to 78 hospitals and Muhammadiyah healthcare facilities across Central Java, East Java, Yogyakarta, DKI Jakarta, West Java, Kalimantan, and Sumatra.
• Ministry of Health of the Republic of Indonesia (KEMENKES RI)coreStrategic or Co-development Partner · 1 October 2021PT Pfizer Indonesia signed a 3-year MoU with KEMENKES RI to support promotive and preventive health efforts in Indonesia. Collaboration areas include pneumonia prevention, metastatic breast cancer and lung cancer awareness, immunization promotion, biotechnology education ecosystem development, and healthcare human capacity building. The MoU was signed on October 1, 2021, witnessed by the US Embassy Deputy Ambassador.
• Tenggara StrategicscoreStrategic or Co-development Partner · 1 August 2021Pfizer Indonesia partnered with Tenggara Strategics to implement the Pfizer Biotech Fellowship and HigherHeight programs, aimed at building biotechnology education and research capacity among Indonesian university students and academics. Tenggara Strategics serves as the program co-implementer providing mentorship coordination, program management, and stakeholder engagement across 11 biotechnology faculties in Indonesia.
• Center for Strategic and International Studies (CSIS)minorStrategic or Co-development Partner · 1 August 2021CSIS Indonesia served as a supporting partner for the Pfizer Biotech Fellowship program, contributing to the thought leadership and ecosystem development objectives of the biotechnology education initiative.
• AmCham IndonesiaminorGTM or Marketing Partner · 1 May 2021Pfizer Indonesia collaborated with the American Chamber of Commerce in Indonesia to host the Healthcare Access Summit 2021, bringing together over 25 insurance, health technology, and financing industry representatives to explore innovative financing mechanisms for preventive healthcare access in Indonesia.
• Habitat for Humanity IndonesiamajorStrategic or Co-development Partner · 1 June 2020Pfizer Foundation supported Habitat for Humanity Indonesia to provide temporary accommodation and transportation for frontline healthcare workers at COVID-19 referral hospitals in Jakarta and Surabaya. Over 200 healthcare workers from RSUP Persahabatan, RSUPN Dr. Cipto Mangunkusumo, and Dr. Soetomo hospitals benefited from the 'Sheltering Those Who Care For Us' program. Additionally, Pfizer donated over 1,800 hazmat suits to 20 hospitals.
• Jhpiego (Johns Hopkins University Affiliate)coreStrategic or Co-development Partner · 1 January 2020Pfizer Foundation funded the SHARE (Strengthening Primary Healthcare) project, implemented by Jhpiego in partnership with Indonesia's Ministry of Health and Bogor Health Office. The project trained approximately 230 community health workers from 30 villages in Bogor district to improve primary healthcare quality and child health outcomes. Pfizer Foundation provided the financial support for this initiative.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• PT Dexa Medica: Leading Indonesian private pharmaceutical manufacturer specializing in prescription medicines, OTC, and herbal products with exports to ASEAN and global markets. Directly comparable as a domestic manufacturer competing for hospital, government, and export channel share.
• Sanofi Indonesia: Indonesian subsidiary of Sanofi, a global biopharmaceutical company with vaccines (including pediatric), specialty care, and general medicines portfolios. Most directly comparable multinational peer competing for KEMENKES immunization tenders and hospital channel share in Indonesia.
• PT Novartis Indonesia: Indonesian subsidiary of Novartis, a global pharmaceutical company focused on innovative medicines in cardiology, oncology, immunology, and ophthalmology. Comparable multinational peer competing in specialty/hospital channel sales and physician engagement in Indonesia.
• PT Bio Farma (Persero): State-owned Indonesian vaccine manufacturer and primary supplier to the national immunization program. Directly competes with Pfizer Indonesia for KEMENKES vaccine tenders, particularly for PCV and pediatric immunization contracts, and serves as the government's preferred local vaccine producer.
• PT GlaxoSmithKline Indonesia: Indonesian subsidiary of GSK, a global biopharmaceutical company with major vaccines and specialty medicines portfolios. Directly comparable multinational peer competing in pediatric and adult vaccines, respiratory, and HIV portfolios via hospital and government channels in Indonesia.
• PT AstraZeneca Indonesia: Indonesian subsidiary of AstraZeneca, a global biopharmaceutical company with oncology, vaccines, and specialty care franchises. Comparable multinational peer competing for hospital channel access, KEMENKES partnerships, and digital HCP engagement in Indonesia.
• PT Bayer Indonesia: Indonesian subsidiary of Bayer, with pharmaceutical (cardiometabolic, women's health, oncology) and consumer health operations. Comparable multinational pharma peer competing for hospital and pharmacy channel access in Indonesia.
• PT Merck Sharp Dohme Indonesia (MSD Indonesia): Indonesian subsidiary of Merck & Co., a major global biopharmaceutical company with strong vaccines, oncology, and specialty care portfolios. Comparable as a multinational pharma subsidiary pursuing KEMENKES partnerships, hospital sales, and digital HCP engagement in Indonesia.

Broad incumbents

• PT Kalbe Farma Tbk: Indonesia's largest domestic pharmaceutical company with manufacturing, distribution, and consumer health operations. Directly comparable as a Jakarta-headquartered pharma company selling prescription medicines, vaccines, and consumer health products to government, hospitals, and retail channels across Indonesia.
• PT Kimia Farma (Persero) Tbk: State-owned Indonesian pharmaceutical manufacturer and distributor with the largest pharmacy retail network in Indonesia. Comparable as a full-spectrum pharma player supplying prescription drugs and vaccines to government health programs, hospitals, and retail pharmacies nationwide.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@pfizer_id
• Facebookfacebook.com/Pfizer
• Instagraminstagram.com/pfizer_id

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Indonesia